Related by context. All words. (Click for frequent words.) 73 hematologic malignancies 72 hematological malignancies 70 ganetespib 69 myeloproliferative disorders 69 Azedra 68 HGS ETR1 68 AEG# 68 hematologic cancers 68 protein kinase inhibitor 67 JAK1 67 solid tumors 67 multi kinase inhibitor 67 huC# DM4 67 Carfilzomib 67 OncoVEX GM CSF 67 TREANDA 66 Xanafide 66 CYT# potent vascular disrupting 66 RGB # 66 hematological tumors 66 XmAb# 66 myelofibrosis polycythemia vera 66 ENMD # 66 Ceflatonin 66 JAK inhibitor 66 HER2 positive metastatic breast 66 AP# [003] 66 tumor malignancies 66 HQK 65 alvespimycin 65 PXD# 65 pediatric acute lymphoblastic 65 MEK inhibitors 65 obatoclax 65 BiTE antibody 65 IMA# 65 JAK2 inhibitors 65 proteasome inhibitor 65 Tyrima 65 enzastaurin 65 Symadex 65 leukemia AML 65 Sudhir Agrawal D.Phil 65 trastuzumab DM1 T DM1 65 liposomal formulation 65 haematological malignancies 65 polymerase inhibitors 65 radiation sensitizer 64 epithelial tumors 64 YONDELIS 64 PS# [001] 64 targeting CD# 64 cell malignancies 64 PRT# 64 investigational humanized monoclonal antibody 64 T#I mutant 64 zanolimumab 64 HGS ETR2 64 erlotinib Tarceva ® 64 OXi# 64 oral prodrug 64 entinostat 64 alpha folate receptor 64 CR# vcMMAE 64 oncology therapeutics 64 chronic lymphocytic leukemia CLL 64 bevacizumab Avastin ® 64 Evoltra ® 64 Aplidin 64 pan HDAC inhibitor 64 TRAIL receptor antibodies 64 glioblastoma multiforme GBM 64 IAP inhibitors 64 cell lymphoma CTCL 64 EndoTAG TM 64 pralatrexate 64 depsipeptide 64 cutaneous T cell 64 talactoferrin 64 CBLC# 64 JAK inhibitors 64 deforolimus 64 tyrosine kinase inhibitor 64 TACI Ig 64 tyrosine kinase inhibitors 64 ocular formulation 64 selective kinase inhibitor 64 IAP inhibitor 64 HSP# inhibitor 64 BRAF inhibitor 63 sodium thiosulfate STS 63 cetuximab Erbitux R 63 imatinib Gleevec ® 63 HGS# 63 Litx 63 Alocrest 63 cancer immunotherapies 63 CYC# 63 FLT3 63 Zolinza 63 Thiarabine 63 SAR# [004] 63 Gleevec resistant 63 amrubicin 63 AMPK activators 63 PEG SN# 63 INGN 63 anticancer agents 63 PNP inhibitor 63 IL# PE#QQR 63 HuLuc# 63 investigational compounds 63 HCV protease 63 anticancer therapies 63 IMGN# 63 RNAi therapeutic targeting 63 radezolid 63 AQ4N 63 adecatumumab 63 investigational therapies 63 dasatinib Sprycel ® 63 histone deacetylase inhibitor 63 T#I mutation 63 relapsed leukemia 63 receptor tyrosine kinase inhibitor 63 docetaxel Taxotere R 63 milatuzumab 63 GRNVAC1 63 investigational monoclonal antibody 63 metastatic RCC 63 cutaneous T 63 HDACi 63 L BLP# 63 therapeutic monoclonal antibody 63 axitinib 63 T#I [002] 62 essential thrombocythemia ET 62 immunological diseases 62 OMP #R# 62 Panzem R NCD 62 MCSP respectively 62 castration resistant prostate cancer 62 B CLL 62 myeloproliferative diseases 62 thymalfasin 62 gastrointestinal stromal tumors GIST 62 superficial bladder cancer 62 SCCHN 62 DXL# 62 OHR/AVR# 62 neuroendocrine cancers 62 Phase #/#a trial 62 Perifosine 62 TG# [003] 62 metastatic malignant melanoma 62 CCX# 62 dose escalation Phase 62 oral antiviral 62 orally administered inhibitor 62 hematological malignancy 62 CD# CEA 62 INCB# [001] 62 Panzem 62 Hsp# inhibition 62 multiple myeloma MM 62 Cloretazine ® 62 relapsed multiple myeloma 62 HspE7 62 GRN#L 62 Targretin 62 Squalamine 62 ALN PCS 62 ponatinib 62 oral picoplatin 62 bafetinib 62 oral ridaforolimus 62 #I TM# 62 preclinically 62 Personalized Immunotherapy 62 Solazed TM 62 Marqibo 62 anticancer therapy 62 MT# MEDI 62 metaglidasen 62 omacetaxine 62 CD# monoclonal antibody 62 PCK# 62 JAK2 inhibitor 62 EGFR inhibitors 62 relapsed ovarian cancer 62 Omacetaxine 62 SARMs 62 proteasome inhibitors 62 chronic myelogenous leukemia CML 62 thalidomide Thalomid 62 imatinib Gleevec 62 vascular disrupting agent 62 BAL# [001] 62 RNAi therapeutic 62 mertansine 62 antibody MT# 62 indolent NHL 62 MDV# 62 NS4A 62 CCR9 antagonist 62 BAY #-# 62 PEP# [003] 62 leukemia CLL 62 histologies 62 Annamycin 62 vinca alkaloids 62 GRN# 62 phase IIb clinical 62 investigational HCV polymerase 62 paclitaxel Taxol ® 62 THR beta agonist 62 kidney urologic 62 refractory chronic lymphocytic 62 MyVax R 62 ALN TTR 62 refractory CLL 62 TELINTRA 62 bendamustine 62 oncology indications 62 antitumor activity 62 cytotoxic 62 Virulizin ® 62 belinostat 62 nucleoside analogs 61 HCV polymerase inhibitors 61 MAGE A3 ASCI 61 refractory chronic myeloid 61 tafamidis 61 lymphoma CTCL 61 elvucitabine 61 VitiGam 61 NEUGENE 61 MT#/MEDI-# 61 IMC A# 61 sunitinib malate 61 Tarvacin TM 61 Nexavar sorafenib 61 maribavir 61 essential thrombocythemia 61 OMAPRO 61 medullary thyroid cancer 61 Trofex TM 61 humanized monoclonal antibody 61 ospemifene 61 ON #.Na 61 immunotherapeutic 61 NovaBay Aganocide compounds 61 Insegia 61 anti leukemic 61 Bortezomib 61 relapsed refractory multiple myeloma 61 ALN TTR# 61 delafloxacin 61 sodium glucose cotransporter 61 Aurora kinase 61 CD# expressing 61 Exherin TM 61 #D#C# 61 PI3K inhibitors 61 huN# DM1 61 Vicinium TM 61 SIRT1 activators 61 cilengitide 61 metastatic renal cell carcinoma 61 HuMax EGFr 61 kinase inhibition 61 seliciclib 61 epigenetic therapies 61 ProLindac 61 HCV protease inhibitor 61 refractory multiple myeloma 61 DCVax ® 61 chronic myeloid leukemia CML 61 INCB# [002] 61 Phase Ib study 61 GLP toxicology studies 61 Hsp# inhibitors 61 myelofibrosis 61 romidepsin 61 HGS ETR1 mapatumumab 61 Hepatocellular Carcinoma HCC 61 Tamibarotene 61 interferon lambda 61 Amigal 61 Fludara ® 61 orally bioavailable 61 AKT inhibitor 61 fusion proteins 61 pertuzumab 61 including eniluracil ADH 61 molecularly targeted 61 humanized antibody 61 TTR gene 61 Cerashield 61 chemopreventive agent 61 rALLy clinical trial 61 Cloretazine 61 ENMD 61 Troxatyl 61 FGFR 61 metastatic melanoma 61 ProMune 61 ASONEP 61 ALN VSP 61 Preclinical studies suggest 61 hormone refractory prostate cancer 61 Nicole Onetto MD 61 HuMax CD4 61 TKM PLK1 61 indibulin 61 ruxolitinib 61 gastrointestinal stromal tumors 61 mTOR inhibitor 61 epothilones 61 anticancer compound 61 vascular disrupting agents 61 systemic fungal infections 61 Fodosine 61 humanized antibodies 61 MKC# MT 61 relapsed refractory 61 AzaSite Plus 61 OMP #M# 61 elacytarabine 61 OncoVEX 61 anti CD# antibodies 61 targeted radiotherapeutic 61 humanized monoclonal antibodies 61 hematological indications 61 omega interferon 61 personalized immunotherapy 61 Proxinium TM 61 docetaxel chemotherapy 61 Telintra 61 Romidepsin 61 angiogenesis inhibition 61 sorafenib Nexavar 61 dasatinib Sprycel 61 standard chemotherapy regimens 61 heavily pretreated 61 Sutent sunitinib 61 imetelstat 61 brostallicin 61 leading oral taxane 61 LHRH antagonists 61 BRAF mutation 61 relapsed SCLC 61 virus HCV protease inhibitor 61 metastatic colorectal cancer 61 Thiovir 61 CA4P 61 PEGylated 61 basal cell carcinoma BCC 60 hypereosinophilic syndrome 60 subcutaneous formulation 60 cediranib 60 ESBA# 60 PSMA ADC 60 investigational oral hepatitis C 60 Campath alemtuzumab 60 panobinostat 60 oncolytic viruses 60 histone deacetylase HDAC inhibitor 60 proliferative diseases 60 lymphoid malignancies 60 Shigamabs ® 60 neratinib 60 pancreatic adenocarcinoma 60 myeloma cells 60 Viprovex TM 60 Telatinib 60 Onconase 60 Voreloxin 60 MGd 60 recurrent glioblastoma 60 novel anticancer 60 Exelixis compounds 60 sunitinib Sutent ® 60 antiviral compounds 60 Panzem NCD 60 phase IIa clinical 60 ELACYT 60 antibody MAb 60 PARP inhibitor 60 docetaxel Taxotere ® 60 Factor VIIa 60 Phase #b/#a clinical 60 APOPTONE 60 Azixa 60 replicon 60 MYDICAR ® 60 Gleevec imatinib mesylate 60 elesclomol 60 MKC# PP 60 TLR9 agonist 60 lenalidomide Revlimid R 60 MOZOBIL 60 humanized anti 60 IMC #B 60 kinase inhibitor 60 OvaRex ® MAb 60 KRAS mutant 60 MEK inhibitor 60 PDE4 inhibitor 60 mitogen activated ERK kinase 60 gefitinib Iressa 60 tumor antigens 60 isoform selective 60 INT# [002] 60 PRTX 60 Genasense ® 60 chemotherapeutic 60 favorable pharmacokinetic profile 60 preclinical xenograft models 60 nonsmall cell lung cancer 60 MGCD# [001] 60 valopicitabine 60 refractory gout 60 Bezielle 60 tanespimycin 60 PDX pralatrexate 60 novel histone deacetylase 60 KSP inhibitor 60 oral proteasome inhibitor 60 Campath ® 60 cetuximab Erbitux 60 myelodysplastic syndromes MDS 60 trastuzumab Herceptin R 60 EndoTAG 60 immunotherapies 60 ganaxolone 60 leukemia ALL 60 cMET 60 Ceflatonin R 60 NXL# 60 registrational trial 60 polycythemia vera PV 60 HRPC 60 FOLOTYN ® 60 novel peptide 60 antisense inhibitors 60 non nucleoside inhibitor 60 volociximab 60 AAG geldanamycin analog 60 K ras mutations 60 atacicept 60 prostate cancer CRPC 60 Pharmos proprietary 60 mTOR inhibitors 60 cetuximab Erbitux ® 60 tiapamil 60 trans retinoic acid ATRA 60 acetonide FA 60 recurrent NSCLC 60 Tezampanel 60 neuroendocrine tumors 60 EGFr 60 XL# XL# XL# XL# 60 rBChE 60 Sym# 60 VQD 60 defensin mimetic antibiotic 60 Darinaparsin 60 non nucleoside 60 HDAC inhibitor 60 Epothilones 60 antiangiogenesis therapies 60 EOquin TM 60 Allovectin 7 ® 60 LymphoStat B TM 60 immunomodulatory 60 octreotide implant 60 tamibarotene 60 rxRNA 60 Phase Ib II 60 resistant ovarian cancer 60 EGFR HER2 60 hematologic disorders 60 M2 subunit 60 hematologic tumors 60 Zybrestat 60 orally dosed 60 midstage trials 60 Kit CD# positive 60 EndoTAGTM 1 60 CD# antibody [001] 60 Phase 1b clinical trials 60 polymerase inhibitor 60 sorafenib Nexavar ® 60 XL# XL# 60 Alpharadin 60 Leukine ® 60 Myelodysplastic syndromes MDS 60 dacetuzumab 60 cytotoxin 60 anticancer therapeutics 59 davunetide intranasal AL 59 Hedgehog inhibitor 59 JAK2 59 Velcade bortezomib 59 trastuzumab Herceptin 59 anti angiogenic agents 59 therapeutic monoclonal antibodies 59 haematologic malignancies 59 metastatic renal cell 59 ADI PEG 59 Onco TCS 59 dirucotide 59 pomalidomide 59 tumor xenograft models 59 ZADAXIN ® 59 monoclonal antibody MAb 59 diagnostic biomarkers 59 CDP# 59 xenograft models 59 Aurora kinase inhibitor 59 EpCAM 59 FavId 59 generation purine nucleoside 59 LEUKINE 59 monoclonal antibody conjugated 59 vinca alkaloid 59 Myocet 59 Seliciclib 59 samalizumab 59 compound PMX # 59 targeted antifolate 59 MyVax 59 GAP #B# 59 PARP inhibitors 59 Phase IIb clinical trials 59 Manja Bouman CEO 59 lymphoid tumors 59 sarcoma melanoma 59 Sphingomab 59 PLK1 SNALP 59 Aurexis 59 predictive biomarkers 59 non nucleoside HCV 59 ATL# [002] 59 selective orally bioavailable 59 Aplidin R 59 anti EGFR antibody 59 phase IIb trial 59 alkylating agent 59 severe hypercholesterolemia 59 antibody fragment 59 trastuzumab Herceptin ® 59 ACV1 59 Celator 59 nucleoside analogues 59 anti angiogenic drugs 59 Atiprimod 59 gemcitabine cisplatin 59 Lenocta TM 59 oritavancin 59 immunomodulator 59 IRX 2 59 NSCLC 59 TRIOLEX 59 PLX cells 59 immatics 59 Tarvacin 59 prostate cancer mCRPC 59 EndoTAG TM -1 59 GSK # 59 corticosteroid dexamethasone 59 bosutinib 59 pancreatic NET 59 Epratuzumab 59 solithromycin 59 Neuradiab 59 lumiliximab 59 XL# anticancer compounds 59 novel VDA molecule 59 Janus Kinase 59 Reverset 59 CTAP# Capsules 59 MEK inhibitor RDEA# 59 esophageal candidiasis 59 preclinical models 59 diabetic neuropathic pain 59 metastatic colorectal 59 DPX Survivac 59 Cannabinor 59 chemotherapeutic drug 59 ONCONASE 59 CEQ# 59 Irinotecan 59 ISIS # 59 Nexavar ® 59 selective androgen receptor modulator 59 ZYBRESTAT 59 Mipomersen 59 bortezomib 59 GSK '# 59 Vorinostat 59 RhuDex ® 59 VEGF inhibitors 59 anticancer compounds 59 EGFR expressing 59 Alessandro Riva 59 antisense drug 59 Behcet uveitis 59 aflibercept VEGF Trap 59 selective immunoproteasome inhibitor 59 anidulafungin 59 compound AEZS 59 cell lymphomas 59 TLK# 59 PI3K/Akt pathway inhibitor 59 eprotirome 59 Interferon alpha 59 malignancies 59 bevacizumab Avastin R 59 adipiplon 59 Amrubicin 59 HDAC Inhibitor 59 multiple myeloma 59 EGF receptor 59 Onalta 59 lupus nephritis 59 riociguat 59 chemotherapeutic agents 59 UPLYSO 59 CINTREDEKIN BESUDOTOX 59 XL# XL# XL# 59 perifosine 59 darinaparsin 59 LymphoStat B 59 prokinetic agent 59 chronic eosinophilic leukemia 59 generation proteasome inhibitor 59 PLX# 59 micafungin 59 ongoing Phase 1b 59 AEGR 59 acyclovir Lauriad R 59 BRIM3 59 Dalbavancin 59 oral Factor Xa 59 Daclizumab 59 Cotara 59 phase IIb study 59 ADP receptor antagonist 59 A3 adenosine receptor 59 antisense drugs 59 Phase Ib 59 pradefovir 59 Entereg R 59 renal cell carcinoma 59 histone deacetylase HDAC 59 Palifosfamide 59 taxane chemotherapy 59 Junovan TM 59 imatinib resistant 59 bardoxolone 59 biologic therapeutics 59 CCR5 antagonist 59 tyrosine kinase inhibitors TKIs 59 triphendiol 59 tubulin inhibitor 59 Ophena 59 Pseudomonas aeruginosa infections 59 cancer mCRC 59 thiazolides 59 selective inhibitor 59 TLR antagonists 59 Poly ICR 59 TLR9 agonists 59 chemotherapeutic agent 59 LEP ETU 59 fibrotic disease 59 ALN HPN 59 VEGFR2 inhibitor 59 MAbs 59 Mepact 59 Tarceva TM 59 celgosivir 59 Homspera 59 clofarabine 59 neovascular diseases 59 stable nucleic acid 59 OncoVex 59 LY# [003] 59 BiTE antibodies 59 ostarine 59 LE DT 59 recurrent ovarian cancer 59 Cloretazine R 59 PSN# [002] 59 MPS IVA 59 CORT # 59 glioblastoma 59 systemically administered 59 commercialize deforolimus 59 pancreatic colon 59 VDAs 59 gemcitabine Gemzar 59 forodesine 59 prophylactic vaccines 59 monoclonal antibody therapeutics 59 rALLy 59 malignant pleural mesothelioma 59 velafermin belinostat 59 Rituxan rituximab 59 lintuzumab SGN 59 registrational 59 cardio renal 59 trastuzumab emtansine T DM1 59 Nanobody ® 59 reversible inhibitor 59 Archexin 59 telaprevir VX 59 pegylated interferons 59 TELCYTA 59 mapatumumab 59 tolevamer 59 small molecule inhibitors 58 monoclonal antibody therapies 58 IMiD 58 NP2 Enkephalin 58 chemotherapeutics 58 noninfectious uveitis 58 elotuzumab 58 HCV 58 ZEVALIN 58 Xcytrin R 58 myelofibrosis MF 58 Phase Ib clinical trials 58 Genasense evaluating 58 haematological cancers 58 heavily pretreated patients 58 ARRY # 58 MNTX 58 siRNA therapeutics 58 preclinical studies 58 HCV protease inhibitors 58 AeroLEF TM 58 voreloxin 58 Panzem R 58 Solazed ™ 58 drug conjugate 58 familial amyloidotic polyneuropathy FAP 58 potent anticancer 58 JAK#/JAK# 58 PORxin 58 follicular non 58 chemotherapy regimens 58 tremelimumab 58 preclinical compounds 58 AEZS 58 HIV integrase inhibitors 58 CD3 monoclonal antibody 58 OvaRex R 58 signal transduction inhibitors 58 sorafenib tablets 58 galiximab 58 anti fibrotic 58 Immunotherapeutic 58 YONDELIS R 58 platinum refractory 58 Triolex 58 DACH platinum 58 Debio 58 inhibitor RG# 58 IgG1 monoclonal antibody 58 papillary renal cell carcinoma 58 ImmunoVEX HSV2 58 vaccines oncolytic virus 58 evaluating tivozanib 58 KIACTA ™ 58 Vidofludimus 58 catheter occlusion 58 gastric pancreatic 58 REP# 58 chemically modified siRNA 58 GEM OS2 58 Akt inhibitor 58 ofatumumab 58 AVN# [001] 58 Advexin 58 Kahalalide F 58 TLR8 agonist 58 anticancer activity 58 recombinant antibodies 58 oxidative stress inducer 58 Dacogen injection 58 Preclinical studies 58 BRAF kinase 58 radiotherapeutic 58 SUTENT 58 EOquin 58 Phase IIb trials 58 iclaprim 58 novel immunomodulatory 58 Friedreich Ataxia FRDA 58 HCD# [002] 58 Phase 2a trial 58 anticancer agent 58 rNAPc2 58 Valortim R 58 S1P antibody 58 NS#/#A protease 58 lapatinib Tykerb 58 ocular diseases 58 palifosfamide 58 Li Fraumeni Syndrome 58 Allovectin 7 58 lung pancreatic 58 motesanib 58 TTF Therapy 58 ATC ovarian cancer 58 nucleotide analogs 58 p# inhibitor 58 adecatumumab MT# 58 Aflibercept 58 calcineurin inhibitors 58 selective inhibition 58 Marqibo TM 58 hematological diseases 58 Phase IIa trials 58 adenoviral 58 refractory ovarian cancer 58 trabectedin 58 posaconazole 58 nonclinical studies 58 Leukine 58 prostone 58 tumors GIST 58 ApoB SNALP 58 Phenoptin 58 epratuzumab 58 hepatitis C HCV 58 androgen independent 58 Cloretazine R VNP#M 58 metastatic CRC 58 recurrent glioblastoma multiforme 58 MORAb 58 TYZEKA 58 oral nucleoside analogue 58 demethylating agent 58 erlotinib Tarceva 58 demonstrated antitumor activity 58 PNT# 58 otelixizumab 58 PTP 1B 58 zalutumumab 58 Clofarabine 58 cytokine refractory 58 evaluating REVLIMID 58 anti amnesic 58 BrachySil 58 nilotinib 58 TKI therapy 58 myeloid 58 MAXY alpha 58 Dr. Aiping Young 58 vidofludimus 58 vemurafenib 58 ZEVALIN ® 58 mRCC 58 Solazed 58 Pradefovir 58 LHRH analogues 58 cyclin dependent kinases CDKs 58 EGFR mutations 58 GW# [003] 58 ISTODAX 58 RNA antagonist 58 Allovectin 7 R 58 BRAF V# mutation 58 SERMs 58 ATL# [001] 58 Hybridon 58 modified glutathione analog 58 sapacitabine 58 myeloproliferative neoplasms 58 IMiDs R 58 MyVax ® 58 angiogenesis inhibitor 58 OZURDEX ® 58 daptomycin 58 SNALP technology 58 Luteinizing Hormone Releasing Hormone 58 Tumour Vascular Disrupting Agent 58 Alemtuzumab 58 Clolar ® 58 Arsenic trioxide 58 NEUGENE antisense 58 ProSavin 58 drug ISA# 58 Glufosfamide 58 squamous 58 Phase 2b trial 58 dasatinib 58 Rigel R# 58 Azedra ™ 58 TOCOSOL Paclitaxel 58 olaparib 58 ZK EPO 58 immunotherapeutics 58 Serdaxin 58 Uvidem 58 novel antiviral therapeutics 58 nucleotide analog 58 anti angiogenic agent 58 midstage studies 58 DOS# 58 GED aPC 58 ceftazidime 58 VEGF receptors 58 Golimumab 58 carfilzomib 58 Nanobody 58 eniluracil 58 Aganocide R 58 flavopiridol 58 superficial basal cell carcinoma 58 Triapine 58 XmAb ® 58 refractory metastatic 58 Enzastaurin 58 Lenocta 58 Vitaxin 58 S/GSK# 58 Plicera 58 refractory cutaneous T 58 GALNS 58 cleavable linker 58 vismodegib 58 GVAX ® 58 HCV infection 58 squalamine 58 Hsp# inhibitor 58 Recombinant interferon alpha 58 hepatocellular carcinoma HCC 58 oral JAK1 58 TG# [001] 58 epithelial cancers 58 peptide antigens 58 taxane 58 Pathway Inhibitor 58 nosocomial pneumonia 58 PI3K delta 58 Panitumumab 58 oral taxane 58 Neogenix 58 invasive candidiasis 58 tumor antigen 58 immune stimulatory 58 Zemiva TM 58 BCR ABL inhibitors 58 delta isoform 58 small molecule defensin 58 Pegasys ® 58 retapamulin 58 Theratope 58 Reolysin 58 Phase #/#a 58 standard chemotherapy regimen 58 Talabostat 58 Trastuzumab 58 psoriasis rheumatoid arthritis 58 Abiraterone acetate 58 Pemetrexed 58 Restanza 58 Prodarsan ® 58 hormone LHRH antagonist 58 Epidermal Growth Factor Receptor 58 NS5b 58 refractory acute myeloid 58 2 inhibitor CYT# 58 systemic anaplastic large 58 castrate resistant prostate cancer 58 cannabinor 58 blinatumomab 58 Combo Stent 58 exon skipping 58 myeloproliferative neoplasms MPNs 58 Phase Ib clinical 58 Talotrexin 58 Amplimexon 58 DAVANAT 58 humanised monoclonal antibody 58 anticoagulant reversing agent 58 Gleevec Glivec 58 siRNA therapeutic 58 ocrelizumab 58 Urocidin 58 PSN# [001] 58 MVA BN R 58 metastatic neuroendocrine tumors 58 SNT MC#